Terms: = Lymphoma AND TNFRSF17, BCMA, 608, ENSG00000048462, CD269, Q02223, BCM
176 results:
1. Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel.
Ghilardi G; Paruzzo L; Patel V; Svoboda J; Chong ER; Fardella E; Chong EA; Gabrielli G; Nasta SD; Landsburg DJ; Carter J; Pajarillo R; Barta SK; White G; Weber E; Napier E; Porter DL; Garfall AL; Schuster SJ; Ruella M
J Hematol Oncol; 2024 Apr; 17(1):19. PubMed ID: 38644469
[TBL] [Abstract] [Full Text] [Related]
2. Machine Learning-Based Survival Prediction Models for Progression-Free and Overall Survival in Advanced-Stage Hodgkin lymphoma.
Rask Kragh Jørgensen R; Bergström F; Eloranta S; Tang Severinsen M; Bjøro Smeland K; Fosså A; Haaber Christensen J; Hutchings M; Bo Dahl-Sørensen R; Kamper P; Glimelius I; E Smedby K; K Parsons S; Mae Rodday A; J Maurer M; M Evens A; C El-Galaly T; Hjort Jakobsen L
JCO Clin Cancer Inform; 2024 Apr; 8():e2300255. PubMed ID: 38608215
[TBL] [Abstract] [Full Text] [Related]
3. bcma-directed therapy, new treatments in the myeloma toolbox, and how to use them.
Rees MJ; Kumar S
Leuk Lymphoma; 2024 Mar; 65(3):287-300. PubMed ID: 38354090
[TBL] [Abstract] [Full Text] [Related]
4. Hepatitis B surface antigen positivity is associated with poor short- and long-term outcomes in patients with diffuse large B-cell lymphoma who received CHOP or R-CHOP.
Zhan Z; Guo W; Wan X; Wang B; Li J; Wang H; Li Z; Huang Y; Young KH; Bai O
Front Immunol; 2024; 15():1324113. PubMed ID: 38318173
[TBL] [Abstract] [Full Text] [Related]
5. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy.
Ghilardi G; Fraietta JA; Gerson JN; Van Deerlin VM; Morrissette JJD; Caponetti GC; Paruzzo L; Harris JC; Chong EA; Susanibar Adaniya SP; Svoboda J; Nasta SD; Ugwuanyi OH; Landsburg DJ; Fardella E; Waxman AJ; Chong ER; Patel V; Pajarillo R; Kulikovskaya I; Lieberman DB; Cohen AD; Levine BL; Stadtmauer EA; Frey NV; Vogl DT; Hexner EO; Barta SK; Porter DL; Garfall AL; Schuster SJ; June CH; Ruella M
Nat Med; 2024 Apr; 30(4):984-989. PubMed ID: 38266761
[TBL] [Abstract] [Full Text] [Related]
6. Bispecific bcma/CD24 CAR-T cells control multiple myeloma growth.
Sun F; Cheng Y; Wanchai V; Guo W; Mery D; Xu H; Gai D; Siegel E; Bailey C; Ashby C; Al Hadidi S; Schinke C; Thanendrarajan S; Ma Y; Yi Q; Orlowski RZ; Zangari M; van Rhee F; Janz S; Bishop G; Tricot G; Shaughnessy JD; Zhan F
Nat Commun; 2024 Jan; 15(1):615. PubMed ID: 38242888
[TBL] [Abstract] [Full Text] [Related]
7. Recent advances and future perspectives of T-cell engagers in lymphoid malignancies.
Shirouchi Y; Maruyama D
Jpn J Clin Oncol; 2024 Apr; 54(4):376-385. PubMed ID: 38183209
[TBL] [Abstract] [Full Text] [Related]
8. Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality.
Rejeski K; Wang Y; Hansen DK; Iacoboni G; Bachy E; Bansal R; Penack O; Müller F; Bethge W; Munoz J; Mohty R; Bücklein VL; Barba P; Locke FL; Lin Y; Jain MD; Subklewe M
Blood Adv; 2024 Apr; 8(8):1857-1868. PubMed ID: 38181508
[TBL] [Abstract] [Full Text] [Related]
9. Immunotherapy targeting B cells and long-lived plasma cells effectively eliminates pre-existing donor-specific allo-antibodies.
Zhang Z; Markmann C; Yu M; Agarwal D; Rostami S; Wang W; Liu C; Zhao H; Ochoa T; Parvathaneni K; Xu X; Li E; Gonzalez V; Khadka R; Hoffmann J; Knox JJ; Scholler J; Marcellus B; Allman D; Fraietta JA; Samelson-Jones B; Milone MC; Monos D; Garfall AL; Naji A; Bhoj VG
Cell Rep Med; 2023 Dec; 4(12):101336. PubMed ID: 38118406
[TBL] [Abstract] [Full Text] [Related]
10. Broadening the horizon: potential applications of CAR-T cells beyond current indications.
Karsten H; Matrisch L; Cichutek S; Fiedler W; Alsdorf W; Block A
Front Immunol; 2023; 14():1285406. PubMed ID: 38090582
[TBL] [Abstract] [Full Text] [Related]
11. [Novel CD19-KIRS2/Dap12-BB CAR-T Treatment for 3 Patients with Relapsed and Refractory B-Cell Tumors].
Ji SW; Hua T; Wang JJ; Shao LY; Chen ZH; Liu JY; Cheng H; Chen W; Sun C; Wang X; Xu KL; Cao J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1860-1865. PubMed ID: 38071073
[TBL] [Abstract] [Full Text] [Related]
12. Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study.
Martin TG; Moreau P; Usmani SZ; Garfall A; Mateos MV; San-Miguel JF; Oriol A; Nooka AK; Rosinol L; Chari A; Karlin L; Krishnan A; Bahlis N; Popat R; Besemer B; Martínez-López J; Delforge M; Trancucci D; Pei L; Kobos R; Fastenau J; Gries KS; van de Donk NWCJ
Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):194-202. PubMed ID: 38052709
[TBL] [Abstract] [Full Text] [Related]
13. [Clinical analysis of long-term survival and influencing factors of chimeric antigen receptor T-cell therapy in relapsed/refractory acute B-cell lymphoblastic leukemia].
Wang Y; Gao QY; Wang H; Zhang D; Gao Y; Miao YD; Zhai XH; Hu XX; Rui XL; Zhang WH
Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):800-804. PubMed ID: 38049330
[No Abstract] [Full Text] [Related]
14. [Development of Novel Gene-Modified T-Cell Therapies(CAR-T, TCR-T)].
Kitano S
Gan To Kagaku Ryoho; 2023 Oct; 50(10):1032-1037. PubMed ID: 38035829
[TBL] [Abstract] [Full Text] [Related]
15. bcma CAR-T cells in multiple myeloma-ready for take-off?
Scheller L; Tebuka E; Rambau PF; Einsele H; Hudecek M; Prommersberger SR; Danhof S
Leuk Lymphoma; 2024 Feb; 65(2):143-157. PubMed ID: 37997705
[TBL] [Abstract] [Full Text] [Related]
16. Cytomegalovirus (CMV) Reactivation and CMV-Specific Cell-Mediated Immunity After Chimeric Antigen Receptor T-Cell Therapy.
Kampouri E; Ibrahimi SS; Xie H; Wong ER; Hecht JB; Sekhon MK; Vo A; Stevens-Ayers TL; Green DJ; Gauthier J; Maloney DG; Perez A; Jerome KR; Leisenring WM; Boeckh MJ; Hill JA
Clin Infect Dis; 2024 Apr; 78(4):1022-1032. PubMed ID: 37975819
[TBL] [Abstract] [Full Text] [Related]
17. Infection epidemiology in relation to different therapy phases in patients with haematological malignancies receiving CAR T-cell therapy.
Garcia-Pouton N; Ortiz-Maldonado V; Peyrony O; Chumbita M; Aiello TF; Monzo-Gallo P; Lopera C; Puerta-Alcalde P; Magnano L; Martinez-Cibrian N; Pitart C; Juan M; Delgado J; Fernandez De Larrea C; Soriano Á; Urbano-Ispizua Á; Garcia-Vidal C
Eur J Haematol; 2024 Mar; 112(3):371-378. PubMed ID: 37879842
[TBL] [Abstract] [Full Text] [Related]
18. [Antibody drug conjugates (ADC) and bispecific antibodies in oncology - report of the 2022 Saint Louis day].
Ranchon F; Chatelut É; Lambert J; Sesques P; Thibault C; Madelaine I; Rioufol C; Diéras V; Cazin JL
Bull Cancer; 2023 Dec; 110(12):1343-1351. PubMed ID: 37827964
[TBL] [Abstract] [Full Text] [Related]
19. Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies.
Kampouri E; Little JS; Rejeski K; Manuel O; Hammond SP; Hill JA
Transpl Infect Dis; 2023 Nov; 25 Suppl 1():e14157. PubMed ID: 37787373
[TBL] [Abstract] [Full Text] [Related]
20. bcma-targeting chimeric antigen receptor T cell therapy for relapsed and/or refractory multiple myeloma.
Fang J; Zhou F
Ann Hematol; 2024 Apr; 103(4):1069-1083. PubMed ID: 37704875
[TBL] [Abstract] [Full Text] [Related]
[Next]
